A Follow-up Study to Evaluate the One-year Post Treatment Effects of Peginterferon Alfa-2a (PEGASYS) in Patients With HBeAg Positive Chronic Hepatitis B From the Original Study ML 22265
Latest Information Update: 19 Jan 2016
At a glance
- Drugs Peginterferon alfa-2a (Primary)
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Roche
Most Recent Events
- 06 Jan 2016 Results published in the Antiviral Therapy
- 11 Mar 2013 New trial record
- 04 Mar 2013 Status changed from active, no longer recruiting, to completed, as reported by ClinicalTrials.gov.